Pharmaceutical News

RSS

UNICEF publishes vaccine costs in an effort to promote price competition

UNICEF for the first time on Friday published the prices it pays pharmaceutical companies for vaccines, "as the world's biggest buyer of lifesaving immunizations aims to spark price competition in the face of rising costs," the Associated Press/Washington Post reports (5/28).

1 Jun 2011

Lymphoma vaccine extends disease-free survival by 14 months

A lymphoma vaccine uniquely tailored for each patient extends disease-free survival by 14 months, with signs of an even better response for patients with a specific biological marker, a team led by scientists at The University of Texas MD Anderson Cancer Center reported today in the online version of Journal of Clinical Oncology.

1 Jun 2011

FDA approves APP Pharmaceuticals' Piperacillin and Tazobactam for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration to market Piperacillin and Tazobactam for Injection, the number one prescribed intravenous antibiotic in the U.S. APP will launch the product immediately.

1 Jun 2011

E64d reduces Aβ levels and improves memory function in brains of Alzheimer's disease mice

Researchers at the University of California, San Diego, the Medical University of South Carolina and American Life Science Pharmaceuticals of San Diego have demonstrated that oral administration of a cysteine protease inhibitor, E64d, not only reduces the build-up of β-amyloid in the brains of animal models for Alzheimer's disease, but also results in a substantial improvement in memory deficit.

1 Jun 2011

Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia

A drug already approved for people with cancer shows early potential as a therapy for a common form of dementia, UT Southwestern Medical Center researchers report.

1 Jun 2011

MorphoSys to start share buy-back

MorphoSys AG announced today the decision to repurchase its own shares on the stock market. Following approval by the Company's Supervisory Board, the Board of Management of MorphoSys AG has resolved to acquire up to 100,000 MorphoSys shares over the stock market during the time period from June 1, 2011 to June 30, 2011. The shares will be used to implement the Company's long-term incentive program for management.

1 Jun 2011

European Commission grants Orphan Drug Designation for CSL Behring's rVIIa-FP to treat hemophilia

CSL Behring announced today that it has been granted Orphan Drug Designations by the European Commission for the development of its recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP), a novel therapy to treat hemophilia A and hemophilia B patients with inhibitors.

1 Jun 2011

Eculizumab effective for treating hemolytic-uremic syndrome from EHEC

In the online version of the New England Journal of Medicine, physicians and scientists in Heidelberg, Montreal, and Paris reported on the successful treatment of three young children who were suffering from a severe hemolytic-uremic syndrome after an infection with enterohemorrhagic Escherichia coli.

1 Jun 2011

Type II diabetes drug may slow or stop breast cancer tumor metastasis

A protein activated by certain drugs already approved for treating Type II diabetes may slow or stop the spread of breast tumors.

1 Jun 2011

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

AVEO Pharmaceuticals, Inc. today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting the RON receptor.

1 Jun 2011

Birth control pill safety issues raised

The U.S. Food and Drug Administration (FDA) has announced that it is looking at results from two studies that showed there is a higher risk of blood clots in women taking new birth control pills containing the compound drospirenone. Some brand names include Yaz, Yasmin, Beyaz, Ocella, Loryna, Gianvi, Safyral, Syeda and Zarah.

1 Jun 2011

FDA approves Oceana's Solesta for treatment of fecal incontinence

Oceana Therapeutics, a global company focused on acquiring, developing and commercializing best-in-class specialty therapeutics, announced that the U.S. Food and Drug Administration has approved Solesta as a treatment for fecal incontinence in adult patients who have failed conservative therapy such as dietary control.

31 May 2011

Defiante, Dyax expand KALBITOR partnership to treat hereditary angioedema

Dyax Corp. and Defiante Farmaceutica S.A., an affiliate of the pharmaceutical group Sigma-Tau, announced today an expansion of their strategic partnership for KALBITOR in the treatment of hereditary angioedema and other therapeutic indications to include development and commercialization rights in Latin America, excluding Mexico and the Caribbean, Taiwan, Singapore and South Korea.

31 May 2011

YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

YM BioSciences Inc., today announced that it has received positive opinions from the Committee for Orphan Medicinal Products of the European Commission to grant Orphan Medicinal Product Designation to its JAK1/JAK2 inhibitor, CYT387, for the treatment of primary myelofibrosis, post-polycythaemia vera myelofibrosis and post-essential thrombocythaemia myelofibrosis.

31 May 2011

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

Affymax, Inc. and Takeda Pharmaceutical Company Limited today announced the submission of a New Drug Application to the U.S. Food and Drug Administration for the investigational agent peginesatide for the treatment of anemia associated with chronic renal failure in adult patients on dialysis.

31 May 2011

BioAlliance's appeals in SpePharm litigation rejected

SpePharm Holding B.V. announces that the appeals lodged by BioAlliance Pharma S.A. - a French company listed on Paris Euronext - before the Paris Court of Appeals have been rejected.

31 May 2011

Scientists develop carbohydrate-based vaccine against C. difficile infection

There is now a promising vaccine candidate for combating the pathogen which causes one of the most common and dangerous hospital infections. An international team of scientists from the Max Planck Institute of Colloids and Interfaces in Potsdam has developed a vaccine based on a carbohydrate against the Clostridium difficile bacterium, which is known to cause serious gastrointestinal diseases mainly in hospitals.

31 May 2011

Pharmaceutical News

UNICEF publishes vaccine costs in an effort to promote price competition

Lymphoma vaccine extends disease-free survival by 14 months

FDA approves APP Pharmaceuticals' Piperacillin and Tazobactam for Injection

E64d reduces Aβ levels and improves memory function in brains of Alzheimer's disease mice

Suberoylanilide hydroxamic acid holds promise against familial frontotemporal dementia

MorphoSys to start share buy-back

European Commission grants Orphan Drug Designation for CSL Behring's rVIIa-FP to treat hemophilia

Eculizumab effective for treating hemolytic-uremic syndrome from EHEC

Type II diabetes drug may slow or stop breast cancer tumor metastasis

Centocor Ortho Biotech, AVEO sign license deal to develop, commercialize RON-targeted antibodies

Birth control pill safety issues raised

FDA approves Oceana's Solesta for treatment of fecal incontinence

Defiante, Dyax expand KALBITOR partnership to treat hereditary angioedema

YM BioSciences' CYT387 receives European Commission positive opinion for Orphan Drug Designation

Takeda, Affymax submit peginesatide NDA to FDA for treatment of anemia linked with chronic renal failure

BioAlliance's appeals in SpePharm litigation rejected

Scientists develop carbohydrate-based vaccine against C. difficile infection

Cancer drug helps prevent hypertensive heart disease

National Pharmacovigilance Programme to increase awareness about benefits of adverse event reporting

Oceana Therapeutics receives FDA approval for Solesta injectable gel to treat fecal incontinence

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News